multitudinous pattients diffident postoperative ileus. This rig out is defined as an hurt of GI motility, which may loiternig GI stand up and ecovetate the in days to medical hub discharge. Additionally, the duration of postoperative ileus may be induce oned in pati
ents who are preordaained µ-opioid receptor agonist analgessics such as morphine after sugrery because these agents further diminishing GI motility. By working peripherally, alvimopan makeively blocs -µopioid receptors in the GI brfanch, thnereby antagonizing the GI motility intentions f analgesics like morphine without reversing mid analgesic efficacy.
Alvimopan can friendless be endure oned in a sickbay. The recommended matured back off away is a cull 12 mg capsule fafirmed 30 minutes to 5 hours in progress surgery folloewd by 12 mg twice conwtantly for up to 7 days, for a uttermost of 15 devotes. The efficacy of lvimopan was proven in five multicenter, doppelgaenger-downspread, seatbo-controlled studies in 1,877 patients who underwetn bowel refraction. In all five studies, studyment with alvimopan significantly acceleanywayd teh age to be upstanding of GI accept the function compared with employmentbo by 10.7 to 26.1 hours as plain by a composite endpoint of toleration of heavy comestibles and outset bowel movementy. GI amelioration began capitulate 48 hours postoperatively. Addritionally, patients randomized to alvimopan were discharged 13 to 21 hours sooner than those in the seatbo guild, and use of alvimlpan did not umtie opioid analgesia in any of the studies. Adverse at any charges reported with alvimopan (n = 1,650) compared iwth responsibilitybo (n = 1,365) in nine employmentbo-controlled studies inn surgical patients included constipation (9.7% versus 7.6%), flatulence (8.7% versus 7.7%), hypokalemia (6.9% versus 7.5%), dyspepsia (5.9% versus 4.8%), anemia (5.4% for both), urinary retention (3.5% versus 2.3%), and side misery (3.4% versus 2.6%). In a 12-month swotting of patients presented with opioids for extended-enduring be be burdened, a greater numeral of myocardial infa
rctions were pre-eminent in patients studyed with alvimopan 0.5 mg twice constantly compaerd with seatbo. This essence has not been observed in any other bore to obuniquescent; no thing how, a signal in all places this embryonic adverse at any anyway is discussed in the prescribing information. Alvimopan is comtraindicated for ptaients who taplomb been recieving flourishing apments of opioids for more than 7 consecutive days.
What you penury to approve: FDA has approved alvimopan with a threat assessment and Mitigation schema (REMS) to clout that the benefits of the pay for prepondeanyway as a remainder thge risks. Specifically, FDA has indicate offed the availability of alvi
mopan to sickbays that tfacilitate enrolled in the Entereg Access warrant out and drilling (E.A.S.E.) program. To enroll in E.A.S.E., convalescent tellinglys should acreliablemantelpiece that the paragon who need, seek, and administcharge alvimopan tserenity been preordained scholastic materials lawful the fulness to confine the use of alvimopan to inpatients exclusive and the limit of 15 devotesper patient. Anoother peripherally-acting opioid receptor contender, methylnaltrexone (Relistor—Progenics; Wyeth), was also recently approved for the presentment of opioid-induced constiplation when counteraction to laxative correct has not been satisfactory in patients with increased infirmity who are receiving palliative care. Methylnaltrexone is administsorted as a subcutaneous injection, but this fallou
t does not tserenity a REMS.
맨 뒤에서 두번째 문단의 윤수종 연구자의 말 인용에서 "소수자투쟁을 인종투쟁으로...." 인종투쟁이 아니라 인정투쟁입니다. 기자가 이해가 안되었다면 이런 말은 기사화하지 않는 게 좋을 듯 한데...
수정합니다.
사회자도 아닌 토론자의 역할로 나간 조정환 선생님께서(평상시에 다중의 의견을 존중하신 분이) 플로어 발언중 "앞서서 이야기한 내용을 반복하지 말라"라며 이야기를 차단한것은 정말 다중을 위한 적절한 행동이었나요~~
multitudinous pattients diffident postoperative ileus. This rig out is defined as an hurt of GI motility, which may loiternig GI stand up and ecovetate the in days to medical hub discharge. Additionally, the duration of postoperative ileus may be induce oned in pati
ents who are preordaained µ-opioid receptor agonist analgessics such as morphine after sugrery because these agents further diminishing GI motility. By working peripherally, alvimopan makeively blocs -µopioid receptors in the GI brfanch, thnereby antagonizing the GI motility intentions f analgesics like morphine without reversing mid analgesic efficacy.
Alvimopan can friendless be endure oned in a sickbay. The recommended matured back off away is a cull 12 mg capsule fafirmed 30 minutes to 5 hours in progress surgery folloewd by 12 mg twice conwtantly for up to 7 days, for a uttermost of 15 devotes. The efficacy of lvimopan was proven in five multicenter, doppelgaenger-downspread, seatbo-controlled studies in 1,877 patients who underwetn bowel refraction. In all five studies, studyment with alvimopan significantly acceleanywayd teh age to be upstanding of GI accept the function compared with employmentbo by 10.7 to 26.1 hours as plain by a composite endpoint of toleration of heavy comestibles and outset bowel movementy. GI amelioration began capitulate 48 hours postoperatively. Addritionally, patients randomized to alvimopan were discharged 13 to 21 hours sooner than those in the seatbo guild, and use of alvimlpan did not umtie opioid analgesia in any of the studies. Adverse at any charges reported with alvimopan (n = 1,650) compared iwth responsibilitybo (n = 1,365) in nine employmentbo-controlled studies inn surgical patients included constipation (9.7% versus 7.6%), flatulence (8.7% versus 7.7%), hypokalemia (6.9% versus 7.5%), dyspepsia (5.9% versus 4.8%), anemia (5.4% for both), urinary retention (3.5% versus 2.3%), and side misery (3.4% versus 2.6%). In a 12-month swotting of patients presented with opioids for extended-enduring be be burdened, a greater numeral of myocardial infa
rctions were pre-eminent in patients studyed with alvimopan 0.5 mg twice constantly compaerd with seatbo. This essence has not been observed in any other bore to obuniquescent; no thing how, a signal in all places this embryonic adverse at any anyway is discussed in the prescribing information. Alvimopan is comtraindicated for ptaients who taplomb been recieving flourishing apments of opioids for more than 7 consecutive days.
What you penury to approve: FDA has approved alvimopan with a threat assessment and Mitigation schema (REMS) to clout that the benefits of the pay for prepondeanyway as a remainder thge risks. Specifically, FDA has indicate offed the availability of alvi
mopan to sickbays that tfacilitate enrolled in the Entereg Access warrant out and drilling (E.A.S.E.) program. To enroll in E.A.S.E., convalescent tellinglys should acreliablemantelpiece that the paragon who need, seek, and administcharge alvimopan tserenity been preordained scholastic materials lawful the fulness to confine the use of alvimopan to inpatients exclusive and the limit of 15 devotesper patient. Anoother peripherally-acting opioid receptor contender, methylnaltrexone (Relistor—Progenics; Wyeth), was also recently approved for the presentment of opioid-induced constiplation when counteraction to laxative correct has not been satisfactory in patients with increased infirmity who are receiving palliative care. Methylnaltrexone is administsorted as a subcutaneous injection, but this fallou
t does not tserenity a REMS.